Literature DB >> 19858944

Community involvement in HIV and tuberculosis research.

Mark Harrington1.   

Abstract

Since advent of the HIV pandemic in the 1980s, affected communities and individuals living with HIV have played key roles in leading the response to the crisis. Achievements of the HIV treatment activist movement include persuading the US Food and Drug Administration to allow expanded access to experimental treatments for those unable to enter controlled clinical trials; accelerated approval of anti-HIV drugs based on surrogate markers such as CD4 cell and HIV RNA changes; and the involvement of people with HIV and their advocates throughout the research system, including in the design, conduct, and evaluation of clinical trials. HIV treatment activists have adapted these skills to tackle tuberculosis (TB) research and programs. Considering the dearth of adequate diagnostic, treatment, and preventive interventions to control TB among people with HIV, the experiences and efforts of HIV activists are vital to accelerate research and development of new diagnostics, drugs, and vaccines to identify, cure, and prevent TB, especially among people living with HIV. Advocacy to implement World Health Organization collaborative HIV/TB activities and to reduce TB's toll among people with HIV provides a case study of how scale-up of HIV and TB programs contributes to health system strengthening.

Entities:  

Mesh:

Year:  2009        PMID: 19858944     DOI: 10.1097/QAI.0b013e3181bbcc56

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  8 in total

Review 1.  From personal survival to public health: community leadership by men who have sex with men in the response to HIV.

Authors:  Gift Trapence; Chris Collins; Sam Avrett; Robert Carr; Hugo Sanchez; George Ayala; Daouda Diouf; Chris Beyrer; Stefan D Baral
Journal:  Lancet       Date:  2012-07-20       Impact factor: 79.321

2.  Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.

Authors:  Hailey J Gilmore; Albert Liu; Kimberly Ann Koester; K Rivet Amico; Vanessa McMahan; Pedro Goicochea; Lorena Vargas; David Lubensky; Susan Buchbinder; Robert Grant
Journal:  AIDS Patient Care STDS       Date:  2013-10       Impact factor: 5.078

3.  How ethical is your clinical trial?

Authors:  L Miller; M Folayan; D Allman; B Nkala; L M Kasirye; L R Mingote; G Calazans; R Mburu; F Ntombela; M Ditmore
Journal:  Int J Clin Pract       Date:  2010-06-16       Impact factor: 2.503

4.  Legal and ethical values in the resolution of research-related disputes: how can IRBS respond to participant complaints?

Authors:  Kristen Underhill
Journal:  J Empir Res Hum Res Ethics       Date:  2014-02       Impact factor: 1.742

5.  Could FDA approval of pre-exposure prophylaxis make a difference? A qualitative study of PrEP acceptability and FDA perceptions among men who have sex with men.

Authors:  Kristen Underhill; Kathleen M Morrow; Don Operario; Kenneth H Mayer
Journal:  AIDS Behav       Date:  2014-02

6.  The HIV/AIDS epidemic in sub-Saharan Africa: thinking ahead on programmatic tasks and related operational research.

Authors:  Rony Zachariah; Wim Van Damme; Vic Arendt; Jean Claude Schmit; Anthony D Harries
Journal:  J Int AIDS Soc       Date:  2011-07-06       Impact factor: 5.396

Review 7.  Improving the prevention, diagnosis and treatment of TB among people living with HIV: the role of operational research.

Authors:  Delphine Sculier; Haileyesus Getahun; Christian Lienhardt
Journal:  J Int AIDS Soc       Date:  2011-07-06       Impact factor: 5.396

8.  HIV cure research: print and online media reporting in Australia.

Authors:  Jennifer Power; Bianca Fileborn; Gary W Dowsett; Jayne Lucke; Graham Brown; Jeanne Ellard; Sharon R Lewin; Joseph D Tucker; Sean Slavin; Jeremy Sugarman; Sophie Hill
Journal:  J Virus Erad       Date:  2017-10-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.